ArticleOpen forum infectious diseases2014

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Mark J Mulligan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.